APC Promoter Hypermethylation as a Prognostic Marker in Breast Cancer Patients

Saelee, Pensri; Pongtheerat, Tanett

doi:10.31557/APJCP.2020.21.12.3627

APC Promoter Hypermethylation as a Prognostic Marker in Breast Cancer Patients

Document Type : Research Articles

Authors

Pensri Saelee ¹
Tanett Pongtheerat ²

¹ Research Division, National Cancer Institute, Bangkok 10400, Thailand.

² Unit of Biochemistry, Department of Medical Sciences, Faculty of Science, Rangsit University, Patumthani, Thailand.

10.31557/APJCP.2020.21.12.3627

Abstract

Background: Adenomatous polyposis coli (APC) promoter hypermethylation implicated in breast cancer development through Wnt signaling pathway, hypermethylation may result in inactivation of APC expression. This study aimed to investigated whether hypermethylation of APC promoter, the aggressive behavior of breast cancer cells, and correlated them with clinicopathological parameters and survival. Methods: Sixty-one fresh tissues of breast tumor were evaluated for APC promoter hypermethylation with methylation-specific PCR techniques (MS-PCR) and APC mRNA expression level analysis by quantitative real-time reverse transcription-PCR. Results: Our results show aberrant APC hypermethylation status was founded in 27 of 61 cases (44%), and significantly associated with chemotherapy treatment (OR= 6.9, 95%CI=1.5-31.01, P = 0.01), distant metastasis (OR = 5.52, 95%CI = 1.27-24.08, P = 0.04) as well as APC methylated status also associated with shorter overall survival than those without (8.4 and 11.0 years respectively, P = 0.02). Conclusion: The findings indicated hypermethylation of APC promoter may be used as a useful prognostic biomarker in breast cancer patients.

Keywords